Ascentage Pharma presented 17 clinical updates on its key cancer drugs olverembatinib and lisaftoclax at the EHA2026 Congress, showing strong efficacy and safety in treating various blood cancers including chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Olverembatinib demonstrated potential as a second-line treatment for resistant CML and showed robust responses in Ph+ ALL patients, while lisaftoclax showed promising results in chronic lymphocytic leukemia (CLL), myeloid neoplasms, and pediatric relapsed/refractory Ph+ ALL. These findings support ongoing global trials and the development of innovative combination therapies to improve patient outcomes worldwide.
The global reactive hot melt adhesives market is projected to grow from $2.02 billion in 2025 to $4.29 billion by 2035, at a CAGR of 7.72%. Growth is driven by regulations limiting solvent-based adhesives, increased use of polyurethane adhesives in a...
The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...
QuickLogic and PQSecure Technologies demonstrated that PQSecure's CRYSTAL-1000C post-quantum cryptographic IP can be efficiently implemented on QuickLogic's reprogrammable eFPGA fabric within SoCs. This allows field-upgradeable security without costl...
Relmada Therapeutics, a clinical-stage biotech company focused on oncology and CNS therapies, will announce its financial results for Q2 2026 on August 6, 2026. The company will host a conference call and webcast to discuss the results and recent bus...
Gilat Satellite Networks Ltd., a global leader in satellite networking technology, will release its second quarter 2026 financial results on August 5, 2026. Following the release, CEO Adi Sfadia and CFO Gil Benyamini will hold a conference call and w...
